With a market cap of $49.6 billion, MetLife, Inc. (MET) is a global financial services company that specializes in insurance, annuities, employee benefits, and asset management. Operating across multiple regions, it offers a wide range of protection, retirement, and savings products to both individual and institutional customers worldwide.

The New York-based company's shares have underperformed the broader market over the past 52 weeks. MET stock has increased nearly 6% over this time frame, while the broader S&P 500 Index ($SPX) has rallied 21.9%. Moreover, shares of MetLife are down 9.9% on a YTD basis, compared to SPX’s 7.8% rise. 

In addition, the insurer stock has also lagged behind the Financial Select Sector SPDR Fund’s (XLF) 22.2% return over the past 52 weeks.

Shares of MetLife fell 2.8% after it reported Q2 2025 adjusted EPS of $2.02, missing analysts’ consensus estimate. Adjusted revenue came in at $17.9 billion, below forecasts, as adjusted premiums, fees, and other revenues declined 6% to $12.7 billion due to weaker underwriting margins in life and non-medical health products. This weakness outweighed a 9% increase in net investment income to $5.7 billion, leading investors to react negatively.

For the fiscal year ending in December 2025, analysts expect MET’s EPS to grow 10.5% year-over-year to $9.11. However, the company’s earnings surprise history is weak. It missed the consensus estimates in the last four quarters. 

Among the 17 analysts covering the stock, the consensus rating is a “Strong Buy.” That’s based on 12 “Strong Buy” ratings, one “Moderate Buy,” and four “Holds.” 

On Jul. 7, Barclays raised MetLife’s price target to $94, maintaining its “Overweight” rating.

As of writing, the stock is trading below the mean price target of $95.40. The Street-high price target of $110 implies a potential upside of 49% from the current price levels.